Cipla surges to record high on earnings
Reuters Market Eye - Shares in Cipla (CIPL.NS) gain as much as 4.06 percent to a record high after the drug maker reported a bigger-than-expected 62 percent surge in July-September net profit.
Despite the surge in share prices, Citigroup says on Tuesday it remains cautious, saying the earnings surprise were mainly driven by the generic version of anti-depressant drug Lexapro, whose exclusivity would tail off in the second half of the fiscal year.
Cipla had earlier given a revenue guidance of up to 12 percent for the current fiscal year, but Citigroup says the company management has now revised its topline growth to 15 percent or above in FY13.
Citigroup adds positives such as better product mix and upside from a weaker rupee appeared factored into estimates and valuations.
The bank raised its target price to 390 rupees from 360 rupees, but retained its 'neutral' rating.
- Tweet this
- Share this
- Digg this
- China's Xiaomi hopes Mi 4 smartphone can take on Apple
- UPDATE 3-Rebels likely downed Malaysian jet 'by mistake' -U.S. officials
- Rebels likely downed Malaysian jet 'by mistake' - U.S. officials
- Analysis - Argentine default in balance as government refuses to capitulate
- Italy gives Google 18 months to change data use practices
The Nifty rose to a record high on Wednesday, led by gains in blue-chips such as ICICI Bank on continued foreign-investor buying, while higher Asian shares also helped sentiment. Full Article
Bullish on Indian equities, but gains seen 'less sharp'- Goldman Sachs Full Article
Jet Airways chairman says looking to restructure debts, talking to bankers Full Article
Honda's India unit to account for 25 pct of Asia Pacific sales by March 2017 - exec Full Article
Supreme Court could allow Sahara boss to conduct asset sale talks, company says. Full Article
Five held in China food scandal probe, including head of Shanghai Husi Food Full Article